Redhill Biopharma and GC Biopharma Advance Public Health with New Anthrax Vaccine

GC Biopharma Launches Revolutionary Anthrax Vaccine to Strengthen National Biosecurity

GC Biopharma, a leading biopharmaceutical company based in Yongin, South Korea, makes a significant stride in public health with the introduction of BARYTHRAX inj., the world's first recombinant anthrax vaccine. Developed in collaboration with the Korea Disease Control and Prevention Agency (KDCA), this groundbreaking vaccine received regulatory approval in April, marking it as Korea's 39th locally developed new drug. The KDCA will utilize BARYTHRAX inj. for national stockpiling, thereby bolstering the country's defenses against biological threats, including potential bioterrorism incidents.

What distinguishes BARYTHRAX inj. from traditional vaccines is its innovative use of recombinant protein technology, focusing exclusively on the purified Protective Antigen (PA) protein. Unlike conventional vaccines that depend on live attenuated strains of Bacillus anthracis, BARYTHRAX inj. aims to provide a safer and more effective immunization option. Clinical trials reveal that the vaccine successfully induces neutralizing antibodies and meets established immunogenicity benchmarks. Furthermore, its safety profile is robust, with only mild and transient side effects reported, such as injection-site pain and fatigue. This strong safety and efficacy record positions BARYTHRAX as a vital tool in enhancing public health measures against anthrax exposure.

GC Biopharma's advanced manufacturing capabilities are noteworthy, with its Hwasun facility capable of producing up to 10 million doses annually. This output translates to enough vaccine for approximately 2.5 million individuals, based on a four-dose regimen. The company emphasizes its readiness to scale production rapidly during emergencies, highlighting its commitment to enhancing national biosecurity. CEO Eun-Chul Huh underscores the strategic importance of this vaccine, stating that it represents not only a technological advancement but also a critical improvement in biodefense and vaccine security through innovation and collaboration.

In addition to its work on BARYTHRAX inj., GC Biopharma is expanding its global presence, recently entering the U.S. market with its product Alyglo® in 2024. The company continues to leverage over 50 years of expertise in developing plasma derivatives and vaccines, focusing on advancements in protein engineering and drug delivery platforms. This strategic expansion aligns with the company's mission to address global health challenges while reinforcing its leadership position in the biopharmaceutical industry.

As GC Biopharma rolls out BARYTHRAX inj., it not only enhances public health infrastructure but also sets a precedent for future vaccine development against biological threats, underscoring the critical role of innovation in safeguarding communities worldwide.